Update on Bimervax® immunogenicity amplitude. Insights on humoral response against XBB.1.5 from an extension study (NTC05142553)

Rev Esp Quimioter. 2023 Dec;36(6):658-660. doi: 10.37201/req/085.2023. Epub 2023 Sep 8.

Authors

C Borralleras, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, J M Eiros, J Castrodeza Sanz, P Arrazola, C Cámara Hijón, M Fernández-Prada, A Gil de Miguel, G Mirada Masip, F Moraga-Llop, D Ocaña Rodríguez, J Puig-Barberà, J Vázquez, J Vergara-Alert, S de Cambra¹

Affiliation

¹ Salomé de Cambra Florensa, HIPRA Human Health, Spain. Phone. +34 972 430 660. salome.decambra@hipra.com.

No abstract available

Keywords: COVID-19; immunogenicity; recombinant protein vaccine.

Publication types

Letter